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ESMO antiemetic guidelines
Despite the relevant progress achieved in the last
20 years, vomiting and, especially, nausea continue to
be two of the most distressing side effects of cancer
chemotherapy. In the late 1990s, several professional
organizations published recommendations on the optimal
antiemetic prophylaxis in patients submitted to chemo-
therapy and radiotherapy.
Subsequently, due to the emergence of new findings
and new antiemetic agents after the first recommenda-
tions from 1997, representatives from several oncology
societies met in Perugia, Italy in 2004 for a conference
organized by the Multinational Association of Supportive
Care in Cancer (MASCC) and updated the antiemetic
guidelines [1]. Due to the publication of several new studies
evaluating the role of the most recently developed antiemetic
drugs, experts from the European Society of Medical
Oncology (ESMO) and from MASCC thought it necessary
to update the recommendations. To achieve this aim, the two
societies organized on June 20–21, 2009 the third Consensus
Conference on antiemetics in Perugia, Italy.
The methodology for the guideline process was based on
a literature review through June 1, 2009 using MEDLINE
(National Library of Medicine, Bethesda, MD, USA) and
other databases, with evaluation of the evidence by an
expert panel composed of 23 oncology professionals in
clinical medicine, medical oncology, radiation oncology,
surgical oncology, oncology nursing, statistics, pharmacy,
pharmacology, medical policy, and decisionmaking (Table 1).
With the participating experts coming from ten different
countries, on five continents, we believe that this is the most
representative and evidence-based guideline process that has
yet been performed.
The panel was comprised of ten committees dealing with
major topics in this field (Table 2). Each committee was
composed of five to seven members and each committee
had one chair and co-chair. Each expert could be part of
three or four committees but could only be a chair or co-
chair of one committee. During the consensus conference,
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the findings of each committee were presented by the chair
to the entire expert panel. Although prevention of acute and
delayed nausea and vomiting induced by highly- and
moderately emetogenic chemotherapy had specific commit-
tees; at the end, these worked together as some of the issues
are inseparable. Finally, the panel discussed the results and
determined the level of evidence and the level of
confidence for the recommendations according to ESMO
and MASCC criteria [1, 2].
To change the 2004 recommendations or for a new
guideline recommendation to be accepted, a consensus of at
least 66% of the expert panelists was needed. As a general
rule, the panel considered changes of 10% or greater to be
sufficient to warrant changing a guideline, given that the
evidence supported this magnitude of benefit.
The results of the Perugia Conference are reported in
this supplement of the Journal of Supportive Care in
Cancer. Each article deals with one of the specific topics
Table 1 Participants in the antiemetic guideline process
Matti Aapro, Institut Multidisciplinaire d’Oncologie, Genolier, Switzerland
Enzo Ballatori, Medical Statistician, Via Pillino 2, Spinetoli, Italy
Emilio Bria, Regina Elena National Cancer Institute, Rome, Italy
Rebecca A. Clark-Snow, Lawrence Memorial Hospital, 325 Maine Street, Lawrence, Kansas, USA
Lawrence H. Einhorn, Walther Cancer Institute, Indianapolis, IN, USA
Birgitte T. Espersen, Aarhus University Hospital, Aarhus, Denmark
Petra Feyer, Clinic of Radiotherapy, Viventes Clinics, Berlin-Neukoelln, Berlin, Germany
Richard J. Gralla, North Shore–LIJ Health System, Hofstra University School of Medicine, Lake Success, New York, NY, USA
Steven M. Grunberg, University of Vermont, Burlington, VT, USA
Jørn Herrstedt, Odense University Hospital, Odense, Denmark
Paul J. Hesketh, Lahey Clinic, Burlington, MA, USA
Karin Jordan, University of Halle, Halle, Germany
Mark G. Kris, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Ernesto Maranzano, Radiation Oncology Centre, “S. Maria” Hospital, Terni, Italy
Alexander Molassiatis, School of Nursing, University of Manchester, Coupland, Manchester, UK
Gary Morrow, University of Rochester Cancer Center, Rochester, NY, USA
Ian Olver, Cancer Council Australia, Sydney, Australia
Bernardo L. Rapoport, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Cynthia Rittenberg, Rittenberg Oncology Consulting, Metairie, LA, USA
Fausto Roila, Medical Oncology Division, Santa Maria Hospital, Terni, Italy
Mitsue Saito, Juntendo University Hospital, Tokyo, Japan
Maurizio Tonato, Umbria Regional Cancer Network, Perugia, Italy
David Warr, Princess Margaret Hospital, University of Toronto, Canada
Table 2 Antiemetic guidelines committees
I Emetogenic classification of antineoplastic agents
II Acute emesis: highly emetogenic chemotherapy
III Delayed emesis: highly emetogenic chemotherapy
IV Acute emesis: moderately emetogenic chemotherapy
V Delayed emesis: moderately emetogenic chemotherapy
VI Emesis induced by minimal or low emetogenic chemotherapy
VII Additional issues: refractory emesis, rescue antiemetic therapy, multiple-day chemotherapy, high dose chemotherapy
VIII Anticipatory emesis
IXa Radiotherapy induced emesis
IXb Antiemetics in children receiving chemotherapy
X Future considerations: research directions, study design, economic considerations
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reported in Table 2 and it has been written by the relative
committee members who were actually participating in the
Conference.
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